3 results about "Flumazenil" patented technology

Provided herein are formulations and methods for reversing incapacitation from intentional poisoning, and can include administering to a subject one or more fast-degrading unit dosage forms or nasal sprays, wherein the fast-degrading unit dosage forms and the nasal sprays comprise flumazenil. The unit dosage forms can be selected from the group consisting of a dissolving lozenge, a lollipop, a sublingual film, and a buccal tablet, and can comprise about 0.2 mg to about 2 mg of flumazenil, and the sublingual film can degrade in the mouth in about 3 to about 6 minutes.

The present application relates to compositions comprising flumazenil and naltrexone and methods of use thereof. In particular, the present invention relates to a pharmaceutical composition comprising a microdose of flumazenil and a microdose of naltrexone, or a pharmaceutically acceptable salt thereof, where the flumazenil and naltrexone are present in a weight ratio of about 25: 1 to about 10: 1, where the composition is in the form of a single dose unit, and wherein the single dose unit comprises flumazenil in an amount that provides a daily microdose in the range of about 250 to about 7,500 micrograms and naltrexone in an amount that provides a daily microdose in the range of about 25 to about 1,000 micrograms. The present invention also relates to methods of treating depression and / or anxiety and / or post traumatic stress disorder (PTSD) using a combination of flumazenil and naltrexone.

The present invention relates to pharmaceutical compositions comprising flumazenil and naltrexone, especially compositions comprising low-dose flumazenil and low-dose naltrexone. The present invention also relates to methods for the use of a combination of flumazenil and naltrexone in the treatment of depression and / or anxiety and / or post-traumatic stress disorder (PTSD).